KR20190016972A - 유전자에 기반한 염증성 장 질환의 진단 - Google Patents

유전자에 기반한 염증성 장 질환의 진단 Download PDF

Info

Publication number
KR20190016972A
KR20190016972A KR1020187037151A KR20187037151A KR20190016972A KR 20190016972 A KR20190016972 A KR 20190016972A KR 1020187037151 A KR1020187037151 A KR 1020187037151A KR 20187037151 A KR20187037151 A KR 20187037151A KR 20190016972 A KR20190016972 A KR 20190016972A
Authority
KR
South Korea
Prior art keywords
gene
ibd
subject
allele
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187037151A
Other languages
English (en)
Korean (ko)
Inventor
더모트 피 맥거번
달린 리
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60326226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190016972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020227003985A priority Critical patent/KR102481305B1/ko
Publication of KR20190016972A publication Critical patent/KR20190016972A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020187037151A 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단 Ceased KR20190016972A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003985A KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339357P 2016-05-20 2016-05-20
US62/339,357 2016-05-20
PCT/US2017/033625 WO2017201461A1 (en) 2016-05-20 2017-05-19 Diagnosis of inflammatory bowel disease based on genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003985A Division KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Publications (1)

Publication Number Publication Date
KR20190016972A true KR20190016972A (ko) 2019-02-19

Family

ID=60326226

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187037151A Ceased KR20190016972A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020247019512A Ceased KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227044940A Ceased KR20230003433A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227003985A Active KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247019512A Ceased KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227044940A Ceased KR20230003433A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227003985A Active KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Country Status (6)

Country Link
US (2) US11549146B2 (enExample)
EP (1) EP3458466B1 (enExample)
JP (3) JP7475811B2 (enExample)
KR (4) KR20190016972A (enExample)
CN (2) CN117286238A (enExample)
WO (1) WO2017201461A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3458466B1 (en) 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
JP2022022994A (ja) * 2020-06-26 2022-02-07 ファイザー・インク Ｔｌ１ａ抗体で炎症性腸疾患を処置する方法
JP2023551602A (ja) * 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
CN115851911B (zh) * 2022-11-25 2025-10-24 南京鼓楼医院 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用
EP4646434A2 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443421A (en) 1982-03-16 1984-04-17 Occidental Chemical Corporation Process for removing particulate impurities from aqueous phosphoric acid
US4707260A (en) 1984-08-27 1987-11-17 Toray Industries, Inc. Solid liquid separation device
US5000850A (en) 1986-09-10 1991-03-19 Engelhard Corporation Apparatus for dewatering an aqueous clay suspension
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
EP1100962A1 (en) 1998-07-25 2001-05-23 AstraZeneca AB Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
JP2004194534A (ja) 2002-12-17 2004-07-15 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患疾患マーカーおよびその利用
PT1673473E (pt) * 2003-10-06 2011-09-19 Novartis Ag Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
WO2006127900A2 (en) 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
EP1963534A2 (en) * 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
US20110217310A1 (en) * 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US20080221056A1 (en) * 2007-02-12 2008-09-11 Johns Hopkins University Early Detection and Prognosis of Colon Cancers
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100055700A1 (en) 2007-02-28 2010-03-04 Cedars-Sinai Medical Center Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
US20150376707A1 (en) 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
US8118175B2 (en) 2007-07-18 2012-02-21 Siemens Industry, Inc. Venting device for a disc filter
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US20100240043A1 (en) * 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
EP2220122A2 (en) 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against tl1a
PT2324126E (pt) 2008-08-12 2014-06-02 Zinfandel Pharmaceuticals Inc Método de identificação de factores de risco da doença de alzheimer
DK2329259T3 (en) 2008-08-29 2016-05-09 Janssen Biotech Inc MARKERS AND PROCEDURES FOR ASSESSING AND TREATING ULCERATIVE COLITIS AND RELATED DISEASES USING A 20-GEN PANEL
JP2010088432A (ja) 2008-09-09 2010-04-22 Kansetsu Saisei Kenkyusho:Kk Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
EP2419529B1 (en) 2009-04-14 2015-05-20 Nestec S.A. Inflammatory bowel disease prognostics
US20130136720A1 (en) 2010-01-15 2013-05-30 Cedars-Sinai Medical Center Methods of using fut2 genetic variants to diagnose crohn's disease
CA2801575A1 (en) * 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
CN103649336A (zh) 2011-05-10 2014-03-19 雀巢产品技术援助有限公司 用于个体化治疗管理的疾病活动性表征方法
EP2710147A1 (en) 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
JP2014518883A (ja) 2011-05-20 2014-08-07 ガバメント・オブ・ザ・ユナイテッド・ステイツ，アズ・リプリゼンテッド・バイ・ザ・セクレタリー，デパートメント・オブ・ヘルス・アンド・ヒューマン・サーヴィシズ Ｔ細胞媒介疾病の病態を改善させるためのｔｌ１ａ−ｄｒ３相互作用の遮断及びその抗体
EA201990698A1 (ru) 2011-06-03 2019-12-30 Ксома Текнолоджи Лтд. Антитела, специфические к tgf-бета
MX352274B (es) 2011-10-21 2017-11-16 Nestec Sa Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
CA2864133A1 (en) 2012-02-10 2013-08-15 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3988673A3 (en) * 2013-05-17 2022-08-03 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
BR112016007474A2 (pt) * 2013-10-09 2017-09-12 Cedars Sinai Medical Center diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal
US11365447B2 (en) * 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
KR102629266B1 (ko) 2016-02-26 2024-01-24 나노테크 에너지, 인크. 탄소질 조성물의 프로세싱을 위한 방법, 디바이스 및 시스템
EP3458466B1 (en) * 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3532489A4 (en) 2016-10-26 2020-07-08 Cedars-Sinai Medical Center ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
US11675142B2 (en) 2018-12-14 2023-06-13 Fujikura Ltd. Ferrule, fiber-equipped ferrule, and method for manufacturing fiber-equipped ferrule

Also Published As

Publication number Publication date
WO2017201461A1 (en) 2017-11-23
JP7392020B2 (ja) 2023-12-05
JP2019516375A (ja) 2019-06-20
KR20220025122A (ko) 2022-03-03
EP3458466A4 (en) 2020-03-04
US11549146B2 (en) 2023-01-10
CN109476698B (zh) 2023-10-17
KR102481305B1 (ko) 2022-12-26
EP3458466A1 (en) 2019-03-27
KR20230003433A (ko) 2023-01-05
JP2022095688A (ja) 2022-06-28
JP2024037945A (ja) 2024-03-19
US20230366028A1 (en) 2023-11-16
CN117286238A (zh) 2023-12-26
US20190194754A1 (en) 2019-06-27
CN109476698A (zh) 2019-03-15
EP3458466B1 (en) 2024-08-07
JP7475811B2 (ja) 2024-04-30
KR20240095363A (ko) 2024-06-25

Similar Documents

Publication Publication Date Title
US20250041457A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102046668B1 (ko) 암 대상자의 예후를 결정하기 위한 방법 및 핵산
KR102481305B1 (ko) 유전자에 기반한 염증성 장 질환의 진단
CA2941594A1 (en) Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20170086027A (ko) 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
AU2023203393A1 (en) Compositions and methods for screening and identifying clinically aggressive prostate cancer
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
EP1729930A2 (en) Methods for identifying risk of osteoarthritis and treatments thereof
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022634A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2018209358A2 (en) Systemic delivery of polypeptides
US20030124536A1 (en) Diagnosis and treatment of vascular disease
CA2887830A1 (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
CN114053413A (zh) 一种col4a4基因作为急性缺血性卒中治疗靶点的应用
KR20150094601A (ko) 성별에 독립적인 연령 결정 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200519

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210512

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210512

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220204

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211106

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210712

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200519

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220303

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220207

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211106

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210712

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210512

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200519

X601 Decision of rejection after re-examination